Novartis (NVS) to Release Earnings on Friday

Novartis (NYSE:NVSGet Free Report) is expected to be releasing its earnings data before the market opens on Friday, January 31st. Analysts expect Novartis to post earnings of $1.80 per share and revenue of $12.86 billion for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Novartis (NYSE:NVSGet Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same quarter in the prior year, the firm posted $1.74 EPS. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Trading Down 1.5 %

Novartis stock opened at $101.85 on Wednesday. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. Novartis has a 12 month low of $92.35 and a 12 month high of $120.92. The stock’s 50 day simple moving average is $100.10 and its two-hundred day simple moving average is $108.64. The firm has a market cap of $208.19 billion, a PE ratio of 11.83, a P/E/G ratio of 1.42 and a beta of 0.57.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank restated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Finally, BMO Capital Markets upped their price objective on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $123.38.

Read Our Latest Research Report on NVS

Novartis Company Profile

(Get Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Further Reading

Earnings History for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.